Published in Cancer Weekly, March 21st, 2006
"SC-560 is a structural analog of celecoxib. Recent studies suggested that SC-560 inhibits the in vivo proliferation of colon and breast cancer cells to an extent similar to that observed in celecoxib, and that SC-560 exerts their growth inhibitory effects in a cyclooxygenase-independent manner. In the current study, we sought to investigate the mechanism by which SC-560 inhibits the growth of human lung cancer cells," scientists in South Korea reported.
"SC-560 more potently inhibited the growth of human A549, H460, and H358 lung cancer cell...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.